Mode
Text Size
Log in / Sign up

tDCS combined with cognitive-behavioral interventions shows no significant benefit over sham for depressive symptomstDCS Plus Talk Therapy Shows No Extra Depression Benefit

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that tDCS combined with cognitive-behavioral interventions shows no significant advantage over sham for MDD symptoms.

This meta-analysis evaluated the efficacy of transcranial direct current stimulation (tDCS) combined with cognitive-behavioral interventions (CBIs) compared to sham tDCS in patients with depressive disorders, specifically focusing on those with a primary diagnosis of major depressive disorder (MDD).

The analysis of 321 patients revealed no significant difference between the intervention and control groups for primary outcomes. The effect size for depressive symptoms in the MDD primary diagnosis group was an SMD of -0.05 (95% CI, -0.44 to 0.34). Secondary analyses also showed no statistically significant differences in depressive symptoms (SMD = -0.03), response rates (RR = 1.08; 95% CI, 0.67 to 1.74), or remission rates (RR = 1.33; 95% CI, 0.74 to 2.38).

The authors note that the evidence is limited by methodological heterogeneity in intervention parameters and insufficient statistical power. Consequently, current evidence does not demonstrate a reliable incremental benefit of adjunctive tDCS over sham when paired with heterogeneous CBIs in patients with depressive disorders.

How this fits prior evidence

This meta-analysis addresses a gap regarding the efficacy of combined neuromodulation and behavioral therapies for MDD. While prior evidence indicates that prefrontal rTMS or theta burst stimulation significantly improves response and remission in MDD, this study finds no significant advantage for tDCS combined with CBIs over sham. The findings suggest that while some neuromodulation techniques are effective, the specific combination of tDCS and heterogeneous CBIs does not currently show a reliable incremental benefit.

A new analysis of past studies looked at whether adding transcranial direct current stimulation (tDCS) to cognitive-behavioral interventions (talk therapy) helps people with depression more than talk therapy alone. The analysis combined data from 321 patients with depressive disorders, focusing on those with major depressive disorder (MDD) as their primary diagnosis. Researchers compared tDCS plus cognitive-behavioral interventions to sham tDCS (a fake treatment) plus the same therapy.

The results showed no significant difference between the two groups for reducing depressive symptoms. In the primary analysis of people with MDD, the difference was tiny and not statistically significant. Secondary analyses also found no significant benefits for depressive symptoms, response rates, or remission rates. In other words, adding tDCS did not appear to provide an extra boost beyond the talk therapy.

Safety information was not reported in the analysis, so we don't have details on side effects or tolerability. The authors note that the studies varied in how they delivered the interventions, and the combined sample may have been too small to detect a real effect. Because of these limitations, the findings should be interpreted with caution.

For now, the evidence does not show a reliable added benefit of tDCS when paired with cognitive-behavioral interventions for depression. If you're considering this treatment, talk to your doctor about what the research means for your situation.

What this means for you:
Adding tDCS to talk therapy didn't show extra benefit for depression in this analysis, but more research is needed.

Common questions

What is tDCS and how is it used for depression?

tDCS is a noninvasive brain stimulation technique that uses a weak electrical current. In this analysis, it was combined with cognitive-behavioral interventions (talk therapy) to see if it improved depression outcomes. The study did not find a significant benefit over sham treatment.

Who was included in this analysis?

The analysis included 321 patients with depressive disorders, with a primary focus on those with major depressive disorder (MDD). The study compared tDCS plus cognitive-behavioral interventions to sham tDCS plus the same therapy.

Did tDCS help with depression symptoms?

No, the analysis found no statistically significant difference in depressive symptoms between the tDCS group and the sham group. The effect sizes were very small, and confidence intervals included zero, meaning no clear benefit was shown.

Are there any safety concerns with tDCS?

The analysis did not report on adverse events, serious adverse events, or tolerability. So we don't have information about side effects from this study. Always discuss potential risks with a healthcare provider.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Depressive disorders are a prevalent psychiatric condition; major depressive disorder (MDD) specifically affects approximately 5.7% of adults worldwide and is associated with high levels of disability and disease burden. Although effective interventions are available, some patients do not achieve adequate remission or response rates. In such cases, clinicians often combine interventions to enhance outcomes. This systematic review evaluated whether adding transcranial direct current stimulation (tDCS) to cognitive-behavioral interventions (CBIs) reduces depressive symptoms and improves response and remission rates versus sham tDCS in a sample of patients with depressive disorders. We searched ClinicalTrials.gov, Embase, Scopus, PubMed, Web of Science, Cochrane, PsycINFO, and Ovid from inception to October 2025. The primary outcome was reduction in depressive symptoms; response and remission rates were secondary outcomes. Standardized mean difference (SMD) and risk ratio (RR) were used as effect measures for continuous and dichotomous outcomes, respectively, within a random-effects model. Only randomized controlled trials (RCTs) selected according to the PICO framework were included. Ten RCTs comprising 321 patients were included. Primary analysis showed no significance between intervention and control in a sample with MDD as primary diagnosis (SMD: −0.05; 95% CI: −0.44 to 0.34; I² = 26%). Secondary analysis did not demonstrate a significant advantage over the control group for any reported outcome: depressive symptoms (SMD = –0.03; 95% CI –0.30 to 0.23; I² = 6%), response (RR = 1.08; 95% CI 0.67 to 1.74; I² = 0%), or remission (RR = 1.33; 95% CI 0.74 to 2.38; I² = 0%). Subgroup analyses of cognitive behavioral therapy (CBT) and cognitive control training (CCT) also showed no significant advantage. In sham-controlled trials, current evidence does not demonstrate a reliable incremental benefit of adjunctive tDCS over sham when paired with heterogeneous CBIs in patients with depressive disorders. These findings should be interpreted with caution because of methodological heterogeneity in intervention parameters and insufficient statistical power. https://osf.io/bf4qt/overview, identifier, 10.17605/OSF.IO/BF4QT
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.